A) Geodon B) Risperdal C) Prolixin D) Zyprexa
A) Zyprexa B) Abilify C) Clozaril D) Invega
A) Invega B) Zyprexa C) Seroquel D) Abilify
A) Abilify B) Risperdal C) Seroquel D) Zyprexa
A) Abilify B) Risperdal C) Geodon D) Seroquel
A) Ziprasidone B) Quetiapine C) Clozapine D) Olanzapine
A) Ziprasidone B) Aripriprazole C) Paliperidone D) Risperidone
A) Seroquel B) Risperdal C) Geodon D) Clozaril
A) Aripiprazole B) Paliperidone C) Ziprasidone D) Clozapine
A) Risperdone B) Quetiapine C) Olazapine D) Paliperidone
A) Aripiprazole and Paliperidone B) Clozapine and Aripiprazole C) Clozapine and Risperadone D) Risperidone and Paliperidone
A) 1-3 B) 2-5 C) 4-5 D) 1
A) 18 B) 12 C) 24 D) 6
A) TRUE B) FALSE
A) Minimize side effects of medication B) Prevent relapse into another psychotic episode C) Develop more adaptive coping skills D) Foster patients' medication compliance
A) several weeks after discontinuation of medication B) directly after discontinuation of medication C) six months after discontinuation of medication D) one year after discontinuation of medication
A) Artane B) Thorazine C) Clozaril D) Symmetrel
A) weight gain more common B) tardive dyskinesia more common C) enhanced efficacy in treatment-resistant patients D) increased effectiveness for positive, negative, and disorganized symptoms
A) Haloperiodol B) Clozapine C) Prochlorperazine D) Risperidone
A) Anxiolitics B) Alcohol C) Anticonvulsants D) Stimulants
A) Beta blockers B) Alcohol C) Merperidine D) Halperiodol
A) Nicotine B) Beta blockers C) Anticonvulsants D) Antacids
A) Beta blockers B) SSRIs C) Alcohol D) Tricyclic antidepressants
A) FALSE B) TRUE
A) Male gender B) Tobacco use C) Drug holidays D) Alcohol use
A) FALSE B) TRUE
A) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. B) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. C) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia. D) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia.
A) Akinesia B) Ataxia C) Acute dystonia D) Akathesia
A) Agranulocytosis B) Postural hypotension C) Neuroleptic Malignant Syndrome D) Gynecomastia
A) TRUE B) FALSE
A) TRUE B) FALSE
A) block D2 receptors in the pituitary gland and inhibit prolactin secretion. B) antagonize the normal dopamine-mediated inhibition of prolactin release. C) agonize the normal dopamine-mediated inhibition of prolactin release. D) block D2 receptors in the pituitary gland and decrease prolactin secretion.
A) neuroendocrine changes B) molecular structure C) hungry hungry hippos D) receptor binding and DA turnover
A) Thioxanthenenes B) Butyrophenones C) Phenothiazines D) Sleepykoaladones
A) Potent; low; lower B) Potent; low; higher C) Weak; high; higher D) Weak; high; lower
A) Hallucinations B) Anhedonia C) Formal thought disorder D) Delusions
A) Autoimmune diseases B) Neurological disorders C) Metabolic disorders D) All of the above E) Endocrine disorders
A) Hallucinogens B) Stimulants C) Opioids D) Alcohol E) All of the above
A) TRUE B) FALSE
A) negative symptoms of Schizophrenia. B) All of the above. C) positive symptoms of Schizophrenia. D) disorganized symptoms of Schizophrenia.
A) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. C) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine.
A) increased tap dancing B) increased rates of synthesis C) increased release of dopamine D) increased rates of firing
A) piperazines B) aliphatics C) thioxanthenes D) piperideines
A) all of the above B) galactorrhea C) genecomastia D) menstrual irregularity
A) Inapsine (droperiodol) B) Benadryl (diphenhydramine) C) Symmetrel (amantadine) D) Cogentin (benztropine) E) Artane (trihexphenidyl)
A) TRUE B) FALSE
A) polypharmacy B) comparative lack of EPS C) actual impact at the biological level D) superior impact on positive symptoms
A) Haldol B) Clozaril C) Abilify D) Invega
A) Risperdal B) Seroquel C) Clorazil D) Geodon |